Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference

Alkermes plc (Nasdaq: ALKS) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025.

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025. The company's management will join a webcast panel discussion titled 'Development of Orexin Receptor Agonist in Sleep-Wake Disorders' at 11:45 a.m. EDT.

The global biopharmaceutical company, focused on neuroscience innovations, maintains a portfolio of commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Their pipeline includes clinical and preclinical candidates for neurological disorders, specifically narcolepsy and idiopathic hypersomnia.

The company operates from its headquarters in Ireland, with additional facilities including a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio. The panel discussion webcast will be accessible through the Investors section of Alkermes' website and remain archived for 14 days.

Argus Session date unavailable

-3.03% session move Open Argus

Details

News Market Reaction – ALKS

The recorded move for ALKS in the trading session of this news was -3.03%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, April 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24^th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-24th-annual-needham-virtual-healthcare-conference-302418938.html

SOURCE Alkermes plc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the focus of Alkermes' panel discussion at the 2025 Needham Healthcare Conference?

Alkermes will participate in a panel discussion about 'Development of Orexin Receptor Agonist in Sleep-Wake Disorders' on April 9, 2025, at 11:45 a.m. EDT.

What therapeutic areas does ALKS currently focus on in their product portfolio?

Alkermes focuses on treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, with additional pipeline candidates for narcolepsy and idiopathic hypersomnia.

Where can investors access Alkermes' (ALKS) Needham Conference presentation?

The presentation can be accessed through the Investors tab on www.alkermes.com and will remain archived for 14 days.

What are the main locations of ALKS operations globally?

Alkermes operates from its headquarters in Ireland, with a corporate office and R&D center in Massachusetts, and a manufacturing facility in Ohio.

What neurological disorders is ALKS developing treatments for in their pipeline?

Alkermes is developing clinical and preclinical candidates for neurological disorders, specifically focusing on narcolepsy and idiopathic hypersomnia.